CoChat

A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta

Carter, Brandon, Huang, Pinghan, Liu, Ge, Liang, Yuejin, Lin, Paulo J. C., Peng, Bi-Hung, McKay, Lindsay G. A., Dimitrakakis, Alexander, Hsu, Jason, Tat, Vivian, Saenkham-Huntsinger, Panatda, Chen, Jinjin, Kaseke, Clarety, Gaiha, Gaurav D., Xu, Qiaobing, Griffiths, Anthony, Tam, Ying K., Tseng, Chien-Te K., Gifford, David K. · 2023 · Frontiers in Immunology

Published version of a preprint

Cited by 10

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Licensed COVID-19 vaccines ameliorate viral infection by inducing production of neutralizing antibodies that bind the SARS-CoV-2 Spike protein and inhibit viral cellular entry. However, the clinical effectiveness of these vaccines is transitory as viral variants escape antibody neutralization. Effective vaccines that solely rely upon a T cell response to combat SARS-CoV-2 infection could be transformational because they can utilize highly conserved short pan-variant peptide epitopes, but a mRNA-LNP T cell vaccine has not been shown to provide effective anti-SARS-CoV-2 prophylaxis. Here we show a mRNA-LNP vaccine (MIT-T-COVID) based on highly conserved short peptide epitopes activates CD8 + and CD4 + T cell responses that attenuate morbidity and prevent mortality in HLA-A*02:01 transgenic mice infected with SARS-CoV-2 Beta (B.1.351). We found CD8 + T cells in mice immunized with MIT-T-COVID vaccine significantly increased from 1.1% to 24.0% of total pulmonary nucleated cells prior to and at 7 days post infection (dpi), respectively, indicating dynamic recruitment of circulating specific T cells into the infected lungs. Mice immunized with MIT-T-COVID had 2.8 (2 dpi) and 3.3 (7 dpi) times more lung infiltrating CD8 + T cells than unimmunized mice. Mice immunized with MIT-T-COVID had 17.4 times more lung infiltrating CD4 + T cells than unimmunized mice (7 dpi). The undetectable specific antibody response in MIT-T-COVID-immunized mice demonstrates specific T cell responses alone can effectively attenuate the pathogenesis of SARS-CoV-2 infection. Our results suggest further study is merited for pan-variant T cell vaccines, including for individuals that cannot produce neutralizing antibodies or to help mitigate Long COVID.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2023.1135815

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 32

  1. Walsh, 2020, Safety and immunogenicity of two RNA-based covid-19 vaccine candidates, N Engl J Med, 383, 10.1056/NEJMoa2027906 · doi:10.1056/nejmoa2027906 · Paper page
  2. Tregoning, 2021, Progress of the COVID-19 vaccine effort: Viruses, vaccines and variants versus efficacy, effectiveness and escape, Nat Rev Immunol, 21, 10.1038/s41577-021-00592-1 · DOI · Paper page
  3. Zhang, 2021, SARS-CoV-2 omicron strain exhibits potent capabilities for immune evasion and viral entrance, Signal Transduct Target Ther, 6, 430, 10.1038/s41392-021-00852-5 · DOI · Paper page
  4. Shuai, 2021, Emerging SARS-CoV-2 variants expand species tropism to murines, EBioMedicine, 73, 10.1016/j.ebiom.2021.103643 · DOI · Paper page
  5. Martinez, 2021, Chimeric spike mRNA vaccines protect against sarbecovirus challenge in mice, Science, 373, 10.1126/science.abi4506 · DOI · Paper page
  6. Cohen, 2022, Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models, Science, 377, 10.1126/science.abq0839 · DOI · Paper page
  7. Liu, 2020, Computationally optimized SARS-CoV-2 MHC class I and II vaccine formulations predicted to target human haplotype distributions, Cell Syst, 11, 131, 10.1016/j.cels.2020.06.009 · DOI
  8. Nathan, 2021, Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses, Cell, 184, 4401, 10.1016/j.cell.2021.06.029 · DOI · Paper page
  9. Liu, 2021, Predicted cellular immunity population coverage gaps for SARS-CoV-2 subunit vaccines and their augmentation by compact peptide sets, Cell Syst, 12, 102, 10.1016/j.cels.2020.11.010 · DOI
  10. Liu, 2022, International conference on learning representations, ICLR
  11. Kreiter, 2008, Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals, J Immunol, 180, 10.4049/jimmunol.180.1.309 · DOI · Paper page
  12. Sahin, 2017, Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer, Nature, 547, 10.1038/nature23003 · DOI · Paper page
  13. Vita, 2018, The immune epitope database (IEDB): 2018 update, Nucleic Acids Res, 47, 10.1093/nar/gky1006 · DOI · Paper page
  14. Kotturi, 2009, Of mice and humans: How good are HLA transgenic mice as a model of human immune responses, Immunome Res, 5, 10.1186/1745-7580-5-3 · DOI
  15. Croft, 2019, Most viral peptides displayed by class I MHC on infected cells are immunogenic, Proc Natl Acad Sci U.S.A., 116, 10.1073/pnas.1815239116 · DOI
  16. Nakiboneka, 2019, Interferon gamma (IFN-γ) negative CD4+ and CD8+ T-cells can produce immune mediators in response to viral antigens, Vaccine, 37, 10.1016/j.vaccine.2018.11.024 · DOI
  17. Halfmann, 2022, SARS-CoV-2 omicron virus causes attenuated disease in mice and hamsters, Nature, 603, 10.1038/s41586-022-04441-6 · DOI · Paper page
  18. Kumari, 2021, Neuroinvasion and encephalitis following intranasal inoculation of SARS-CoV-2 in K18-hACE2 mice, Viruses, 13, 10.3390/v13010132 · DOI · Paper page
  19. Moss, 2022, The T cell immune response against SARS-CoV-2, Nat Immunol, 23, 10.1038/s41590-021-01122-w · DOI · Paper page
  20. de Silva, 2021, The impact of viral mutations on recognition by SARS-CoV-2 specific T cells, iScience, 24, 10.1016/j.isci.2021.103353 · DOI
  21. Redd, 2021, CD8+ T cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants, medRxiv, 12, 10.1101/2021.02.11.21251585 · DOI
  22. Benjamini, 2022, Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia, Haematologica, 107, 10.3324/haematol.2021.279196 · DOI
  23. Heitmann, 2022, A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity, Nature, 601, 10.1038/s41586-021-04232-5 · DOI · Paper page
  24. Pardieck, 2022, A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection, Nat Commun, 13, 3966, 10.1038/s41467-022-31721-6 · DOI
  25. Sekine, 2020, Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19, Cell, 183, 158, 10.1016/j.cell.2020.08.017 · DOI · Paper page
  26. Shree, 2022, Shree T. Can B cell-deficient patients rely on COVID-19 vaccine-induced T-cell immunity, Br J Haematol, 197, 659, 10.1111/bjh.18210 · DOI
  27. Kingstad-Bakke, 2022, Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants, Proc Natl Acad Sci U.S.A., 119, 10.1073/pnas.2118312119 · DOI
  28. Matchett, 2021, Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity, J Immunol, 207, 10.4049/jimmunol.2100421 · DOI · Paper page
  29. Ellis, 2000, Frequencies of HLA-A2 alleles in five U.S. population groups. predominance of A*02011 and identification of HLA-A*0231, Hum Immunol, 61, 10.1016/s0198-8859(99)00155-x · DOI · Paper page
  30. Pavord, 2021, Clinical features of vaccine-induced immune thrombocytopenia and thrombosis, N Engl J Med, 385, 10.1056/NEJMoa2109908 · DOI · Paper page
  31. de Oliveira, 2022, Brazillian VITT investigative collaboration group. vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: Description of a series of 39 cases in Brazil, Vaccine, 40, 10.1016/j.vaccine.2022.06.014 · DOI
  32. Swank, 2022, Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae, Clin Infect Dis, 76, 10.1093/cid/ciac722 · DOI · Paper page

Cited by

See all 10

Metadata

Authors
Carter, B., Huang, P., Liu, G., Liang, Y., Lin, P. J. C., Peng, B.-H., McKay, L. G. A., Dimitrakakis, A., Hsu, J., Tat, V., Saenkham-Huntsinger, P., Chen, J., Kaseke, C., Gaiha, G. D., Xu, Q., Griffiths, A., Tam, Y. K., Tseng, C.-T. K., & Gifford, D. K.
Venue
Frontiers in Immunology
Published
2023-03-09
Volume
14
ISSN
1664-3224
Cited by
10
References
10

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta. https://app.cochat.ai/papers/10.3389/fimmu.2023.1135815
The paper
Carter, B., Huang, P., Liu, G., Liang, Y., Lin, P. J. C., Peng, B.-H., McKay, L. G. A., Dimitrakakis, A., Hsu, J., Tat, V., Saenkham-Huntsinger, P., Chen, J., Kaseke, C., Gaiha, G. D., Xu, Q., Griffiths, A., Tam, Y. K., Tseng, C.-T. K., & Gifford, D. K. (2023). A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1135815

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.